Close Menu

By Justin Petrone

Agilent Technologies and Febit this week separately announced expansions to their sequence-capture product lines, while Roche NimbleGen discussed plans to grow its seq-cap portfolio by year end.

Clients of these firms use sequence capture, an application also known as target enrichment and targeted resequencing, to select specific target sequences for deep sequencing on second-generation tools sold by Illumina, Life Technologies' Applied Biosystems, and Roche 454 Life Sciences.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.